Dr Satoru Miura speaks to ecancer about the UpSwinG study.

It is a real-world, non-interventional cohort study on TKI activity in patients with EGFR mutation-positive (EGFRm ) NSCLC with uncommon mutations. Initially, he explains the background of the study.

Dr Miura then mentions the methodology of the UpSwinG study.

He also discusses the results and future impact of this study. EGFR TKIs were the preferred tx option in patients with uncommon EGFR mutations.

Dr Miura mentions that response was highest in patients with major rare compound mutations.

Data were in line with recent analyses of afatinib in rare mutations.

The study concludes that Tx with an EGFR TKI should be considered as standard for patients with uncommon mutations, although many ex20ins were not responsive.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.